FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Scientists raise warnings over MS drug study risks

American scientists are raising a red warning flag over proposed studies of the drug minocycline for several neurodegenerative conditions. Reporting in Lancet Neurology, the researchers say that patients taking the off-patent minocycline for Lou Gehrig's disease declined more rapidly than the control group taking a placebo. That report comes as Canada's MS Society is funding a Phase III trial to determine if the drug can work to slow MS if it is administered during the early stage of the disease.

- check out the report from the Canadian Press

Related Articles:
Antibody stimulates natural repair of MS damage. Report
Natural protein used to combat multiple sclerosis. Report

More stories about Phase III   multiple sclerosis   Canada   antibody   patent  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 80 + 4?
To combat spam, please solve the math question above.